A phase I study of concomitant therapy with proteasome inhibitor PS-341 [bortezomib] and radiation in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Trial Profile

A phase I study of concomitant therapy with proteasome inhibitor PS-341 [bortezomib] and radiation in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Sep 2011 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
    • 29 Sep 2011 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
    • 29 Sep 2011 Actual initiation date changed from Mar 2001 to Feb 2001 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top